A Phase 2 interventional study of DUR-928 and Placebo in SARS-CoV-2, sponsored by Durect. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-05.
Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
Durect is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
First submitted before Durect became part of Bausch Health Companies Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DUR-928
Drug: Placebo
IV infusion
IV infusion
Composite Endpoint of Alive and Free of Organ Failure at Day 28
Free of mechanical ventilation, free of renal replacement therapy and free of acute liver failure
Time frame: Day 28
Alive at Days 28 and 60
Time frame: Day 28 and Day 60
Alive, Out of ICU, at Day 28
Time frame: Day 28
Alive, Out of Hospital, at Days 28 and 60
Time frame: Day 28 and Day 60
| Milestone | DUR-928 | Placebo |
|---|---|---|
| Started | 2 | 0 |
| Completed | 0 | 0 |
| Not completed | 2 | 0 |
| Withdrew: Death | 2 | 0 |
Free of mechanical ventilation, free of renal replacement therapy and free of acute liver failure
| Participants | DUR-928 | Placebo |
|---|---|---|
| Composite Endpoint of Alive and Free of Organ Failure at Day 28 | 0 | 0 |
| Participants | DUR-928 | Placebo |
|---|---|---|
| Alive at Days 28 and 60 | 0 | 0 |
| Participants | DUR-928 | Placebo |
|---|---|---|
| Alive, Out of ICU, at Day 28 | 0 | 0 |
| Participants | DUR-928 | Placebo |
|---|---|---|
| Alive, Out of Hospital, at Days 28 and 60 | 0 | 0 |
Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DUR-928 | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Placebo | — | — | — |
| Event | DUR-928 | Placebo |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/2 | — |
| Brain InjuryNervous system disorders | 1/2 | — |
| Event | DUR-928 | Placebo |
|---|---|---|
| PyrexiaGeneral disorders | 2/2 | — |
| HyperkalaemiaMetabolism and nutrition disorders | 2/2 | — |
| Deep Vein ThrombosisVascular disorders | 2/2 | — |
| HypotensionVascular disorders | 2/2 | — |
| AnaemiaBlood and lymphatic system disorders | 1/2 | — |
| BradycardiaCardiac disorders | 1/2 | — |
| Activated Partial Thromboplastin Time ProlongedInvestigations | 1/2 | — |
| HypokalaemiaMetabolism and nutrition disorders | 1/2 | — |
| HyponatraemiaMetabolism and nutrition disorders | 1/2 | — |
Study terminated early due to lack of enrollment.
| Age, Categorical(Participants) | DUR-928 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 0 | 1 |
| >=65 years | 1 | 0 | 1 |
| Age, Continuous(years) | DUR-928 | Placebo | Total |
|---|---|---|---|
| Mean | 66.5 ± 16.26 | — | 66.5 ± 16.26 |
| Sex: Female, Male(Participants) | DUR-928 | Placebo | Total |
|---|---|---|---|
| Female | 2 | 0 | 2 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | DUR-928 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DUR-928 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 2 | 0 | 2 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Mar 2021, 5 months.
Results were first posted in Aug 2022, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Larsucosterol